我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

连续静脉血液滤过治疗对血浆NT-proBNP水平的影响及其意义

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第4期
页码:
498-502
栏目:
临床研究
出版日期:
2012-08-25

文章信息/Info

Title:
Changes and significance of plasma NT-proBNP level in patients treated with continuous veno-venous hemofiltration
作者:
李 昊1; 2; 殷艳蓉2; 田 刚2
(西安交通大学第一附属医院：1.重症医学科，2.心内科，陕西 西安 710061)
Author(s):
LI Hao1; 2;  YIN Yan-rong2;  TIAN Gang2
(1.Department of Critical Care Medicine, 2.Department of Cardiology, First Affiliated Hospital, Medical College, Xi’an Jiaotong University, Xi’an, 710061, Shaanxi, China)
关键词:
N端脑钠尿肽原; 心功能; 血液滤过
Keywords:
NT-proBNP;  heart function;  hemofiltration
分类号:
R459.5
DOI:
-
文献标识码:
A
摘要:
目的:研究连续静脉血液滤过(CVVH)对N端脑钠尿肽原(NT-proBNP)的影响，以及此类患者CVVH治疗前后NT-proBNP的水平和心功能的相关性。方法： 对50例接受CVVH治疗患者的临床资料进行回顾性分析，收集CVVH治疗前后的血样，采用电化学发光免疫技术检测血浆NT-proBNP的水平，并比较NT-proBNP水平在血液净化治疗前后的变化及其与左室射血分数(LVEF)的相关性。结果： 血浆NT-proBNP的水平在CVVH治疗前明显高于治疗后（P<0.01）。CVVH治疗前NT-proBNP的水平与LVEF呈负相关性（Pearson系数为-0.783），治疗结束后此种相关性消失。CVVH治疗前，死亡组患者NT-proBNP的水平高于存活组患者（P<0.01）。治疗结束后，两组患者血浆NT-proBNP的水平无统计学差异。结论： CVVH治疗可以使血浆NT-proBNP的水平显著下降，且NT-proBNP水平下降的程度与CVVH治疗的时间及脱水量呈正相关。对于接受CVVH治疗及肾功能不全的患者，需慎重以NT-proBNP的水平作为评价心功能的血清学指标。
Abstract:
AIM:To explore the influence and significance of serum NT-proBNP level in patients treated with continuous veno-venous hemofiltration (CVVH) and to investigate the relationship of NT-proBNP and heart function before and after CVVH therapy. METHODS: Clinical data of 50 patients treated with CVVH therapy were retrospectively analyzed. The level of NT-proBNP was measured by electrochemiluminescence immunoassay and the changes of NT-proBNP with LVEF were compared before and after CVVH therapy. RESULTS: The NT-proBNP level before CVVH therapy was significant higher than that after CVVH therapy (P<0.01). Before CVVH therapy, NT-proBNP was closely related to LVEF (Pearson correlation is -0.783), whereas after CVVH the correlation of NT-proBNP and LVEF disappeared. Before CVVH therapy, the NT-proBNP level of nonsurvivors was higher than that of survivors, whereas after CVVH no statistically difference was observed between nonsurvivors and survivors. CONCLUSION: CVVH therapy significantly decreases plasma NT-proBNP level and the descent is closely related to the amount of dehydration and time of CVVH therapy. As a biochemical marker to evaluate the heart function of patient, NT-proBNP should be cautiously used in patients with renal insufficiency and patients treated with CVVH.

参考文献/References

[1]Omland T.Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure[J].Crit Care Med,2008,36(1 suppl):17-27.

[2]Wang AY,Lai KN.Use of cardiac biomarkers in end-stage renal disease[J].J Am Soc Nephrol, 2008,19(9):1643-1652.

[3]Nishikimi T,Kuwahara K,Nakao K.Current biochemistry,molecular biology,and clinical relevance of natriuretic peptides[J].J Cardiol,2011,57(2):131-140.

[4]Nishikimi T, Minamino N, Ikeda M, et al. Diversity of molecular forms of plasma brain natriuretic peptide in heart failure:different proBNP-108 to BNP-32 ratios in atrial and ventricular overload[J].Heart,2010,96(6):432-439.

[5]Dautin G,Boudjeltia S,Soltani Z,et al.The changes in NT-proBNP plasma concentrations during dialysis are highly dependent of the dialysis membrane ultrafiltration coefficient[J].Clinica Chimica Acta,2007,376(1-2):237-239.

[6]Bargnoux AS,Klouche K,Fareh J,et al.Prohormone brain natriuretic peptide(proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration[J].Clin Chem Lab Med,2008,46(7):1017-1024.

[7] Januzzi JL,Morss A,Tung R,et al.Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study[J].Crit Care,2006,10(1):R37.

[8]Kuwahara K,Saito Y,Harada M,et al.Involvement of cardiothrophin-1 in cardiac myocyte-nonmyocyte interactions during hyperthrophy of rat cardiac myocytes in vitro[J]. Circulation,1999,100(10):1116-1124.

[9]Witthaut R,Busch C,Fraunberger P,et al.Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis associated left ventricular dysfunction[J].Intensive Care Med,2003, 29(10):1696-1702.

[10]Baggish AL,Kimmenade RR,Januzzi JL.Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure[J].Am J Cardiol,2008,101(3A):49-55.

[11]Forfia PR,Watkins SP,Rame JE,et al.Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit[J].J Am Coll Cardiol,2005,45(10):1667-1671.

[12]Chenevier-Gobeaux C,Claessens YE,Voyer S,et al.Influence of renal function on N-terminal pro-brain natriuretic peptide(NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: Comparison with brain natriuretic peptide(BNP)[J].Clin Chimica Acta,2005,361(1-2):167-175.

备注/Memo

备注/Memo:
收稿日期: 2012-01-04.基金项目：国家自然科学基金项目资助(30871042) 通讯作者：田刚，主任医师，主要从事高血压、冠心病的临床治疗与研究Email：tiangang36@yahoo.com 作者简介：李昊，助理研究员，博士生Email：lihao215@stu.xjtu.edu.cn
更新日期/Last Update: 2012-07-20